S.Biomedics Co., Ltd. (KOSDAQ:304360)

Market Cap	411.81B +43.4%
Revenue (ttm)	16.96B +30.3%
Net Income	-9.58B
EPS	-810.50
Shares Out	12.39M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	62,784
Average Volume	92,106
Open	33,050
Previous Close	33,750
Day's Range	32,350 - 33,900
52-Week Range	17,930 - 42,600
Beta	1.24
RSI	44.07
Earnings Date	Mar 27, 2026

About S.Biomedics

S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson’s disease; FECS-Ad, which is 1/2a for the treatment of critical limb ischemia; FECS-DF, which is in phase 1/2 clinical development for the treatment of crows feet; TED-R for the treatment of macular degeneration...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 304360

Financial Performance

In 2024, S.Biomedics's revenue was 13.73 billion, an increase of 4.77% compared to the previous year's 13.11 billion. Losses were -6.69 billion, -35.17% less than in 2023.